Impel Pharmaceuticals Inc.
IMPLNASDAQHealthcare
$0.04
$-0.02(-27.27%)
Market Cap$956000
P/E Ratio—
52W High$4.2
52W Low$0.0212
Impel Pharmaceuticals Inc.（IMPL）· 损益表
年度 / 季度 / TTM 视图 · SEC 10-K 与 10-Q（经 FMP 聚合）· 可在下方切换周期与 M/B/T 单位。
FMP · IMPL · 截至 2026-06-09
财务报表
Revenue · Gross Profit · Net Income
| Breakdown | 2022-12 | 2021-12 | 2020-12 | 2019-12 |
|---|---|---|---|---|
| Revenue | ||||
| Revenue | $12.65M | $0.67M | $0.00M | $0.00M |
| Cost of Revenue | $6.50M | $0.69M | $0.00M | $0.00M |
| Gross Profit | $6.16M | ($0.02M) | $0.00M | $0.00M |
| Gross Margin %(computed) | 48.66% | -3.44% | — | — |
| Operating Expenses | ||||
| R&D Expenses | $11.46M | $20.56M | $27.29M | $28.81M |
| G&A Expenses | $77.89M | $50.90M | $18.05M | $12.75M |
| Total Operating Expenses | $89.34M | $71.46M | $45.33M | $41.57M |
| Operating Income | ($83.18M) | ($71.49M) | ($45.33M) | ($41.57M) |
| Operating Margin %(computed) | -657.48% | — | — | — |
| Interest Income | $10.58M | $2.25M | $0.00M | $0.42M |
| Interest Expense | $13.84M | $0.00M | $0.00M | $0.00M |
| Income Before Tax | ($106.31M) | ($76.53M) | ($45.80M) | ($41.83M) |
| Income Tax Expense | $23.13M | $0.00M | $0.00M | $0.03M |
| Net Income | ($129.44M) | ($76.54M) | ($45.80M) | ($41.86M) |
| Net Margin %(computed) | — | — | — | — |
| Per Share & EBITDA | ||||
| EPS (Basic) | $-5.52 | $-5.24 | $-3.49 | $-3.19 |
| Wtd Avg Shares | 23.45M | 14.60M | 13.14M | 13.14M |
| EBITDA | ($91.28M) | ($70.40M) | ($44.26M) | ($40.84M) |
| EBITDA Margin %(computed) | -721.44% | — | — | — |
数据来源：Financial Modeling Prep · 最后更新：2026-06-09 · USD · M
深入了解Impel Pharmaceuticals Inc.
关于Impel Pharmaceuticals Inc.（IMPL）损益表
Impel Pharmaceuticals Inc.（IMPL）损益表数据来源于SEC Form 10-K及10-Q申报文件。2022财年，IMPL实现营收$0.01B，毛利润$0.01B（毛利率48.66%），净利润($0.13B)（净利率-1023.08%）。
常见问题
IMPL · 4 问Impel Pharmaceuticals Inc.（IMPL）2022财年营收为$0.01B，同比up1794.0%。
IMPL revenueIMPL salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09